Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Other Accumulated Expenses (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed Other Accumulated Expenses for 4 consecutive years, with $28658.0 as the latest value for Q3 2025.

  • On a quarterly basis, Other Accumulated Expenses fell 33.83% to $28658.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $28658.0, a 33.83% decrease, with the full-year FY2024 number at $60035.0, up 207.9% from a year prior.
  • Other Accumulated Expenses was $28658.0 for Q3 2025 at bioAffinity Technologies, down from $112590.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $112590.0 in Q2 2025 to a low of $1751.0 in Q2 2024.
  • A 4-year average of $29020.4 and a median of $16210.0 in 2023 define the central range for Other Accumulated Expenses.
  • Peak YoY movement for Other Accumulated Expenses: crashed 64.98% in 2024, then surged 6330.04% in 2025.
  • bioAffinity Technologies' Other Accumulated Expenses stood at $5852.0 in 2022, then skyrocketed by 233.19% to $19498.0 in 2023, then soared by 207.9% to $60035.0 in 2024, then tumbled by 52.26% to $28658.0 in 2025.
  • Per Business Quant, the three most recent readings for BIAF's Other Accumulated Expenses are $28658.0 (Q3 2025), $112590.0 (Q2 2025), and $44205.0 (Q1 2025).